Aethlon Medical Presents at National AIDS Conference

SAN DIEGO, Apr 13, 2005 - Aethlon Medical, Inc. (OTCBB: AEMD) announced that the Company presented yesterday evening at the American Foundation for AIDS Research (amfAR) National HIV/AIDS Update Conference in Oakland, California. The presentation, which highlighted the clinical development of the Aethlon Hemopurifier(TM) to control HIV drug resistance, was given by Aethlon Medical Chief Scientific Officer, Dr. Richard Tullis.

Dr. Tullis stated, "We are very appreciative to have the opportunity to discuss our clinical efforts with an audience that clearly understands that HIV drug resistance is inevitable for the vast majority of infected patients." Mr. David Miller, a member of the New York City HIV Planning Council Advisory Group, stated, "The emergence of HIV drug resistance is becoming a state of emergency for thousands of patients in the U.S. without further clinical options." Mr. Miller continued, "We've seen this develop in New York City and hope that new developments like the Hemopurifier will buy HIV drug resistant patients some significant time until new drugs are available."

About the Conference

One of the most informative annual HIV/AIDS meetings in the United States, the National HIV/AIDS Update Conference attracts health care professionals, service providers, community advocates, and people living with HIV/AIDS. Organized by the American Foundation for AIDS Research (amfAR), it presents that latest information on critical prevention, treatment, and care issues, aiming to translate research advances into practical strategies to help end the AIDS pandemic and improve the lives of people living with HIV/AIDS.

About Aethlon Medical

Aethlon Medical is pioneering the development of viral filtration devices to treat HIV/AIDS, Hepatitis-C (HCV), and pathogens that are mass casualty biological warfare candidates. Each treatment application employs the use of a proprietary technology known as the Hemopurifier(TM), which is designed to rapidly reduce the presence of infectious disease and toxins in the body. The Hemopurifier converges the established scientific principals of affinity chromatography and hemodialysis as a means to augment the immune response of clearing viruses and toxins from the blood before cell and organ infection can occur. More information on Aethlon Medical and the Hemopurifier technology is available at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.

SOURCE: Aethlon Medical, Inc.


Aethlon Medical, Inc. is a featured Company on HomelandDefenseStocks.com

For full details, click here: http://www.homelanddefensestocks.com/Companies/AethlonMedical/Default.asp

Aethlon Medical, Inc.
Anne Hoversten, 858-459-7800 x300 (Investor Relations)
anne@aethlonmedical.com